Kevin Stein at TransDigm Group

Posted on

Kevin Stein, CEO of TransDigm Group (“TDG”), a leading “designer, producer and supplier of highly engineered aircraft components,” gazed out his office window, playing back his conversation with CFO Michael Lisman from November 8, 2018. The debate du jour: does General Electric's innovation in Additive Manufacturing pose a threat to TDG's dominance of their end-market?

As 3D printing drugs in rural hospitals becomes a reality, what are the opportunities and threats for AstraZeneca?

In rural hospitals, critical drugs are often not in stock. Desperate patients and their families are further pushed into prolonged suffering. Feeling they have nothing to lose, some resort to DIY solutions.

As additive manufacturing is applied to drug production at patients’ closest point of sale, we can imagine a world where rural patients purchase out-of-stock drugs within a few hours of visiting a local hospital. What if the hospital had a 3D printer? What if CAD files from global pharmaceutical companies like AstraZeneca were available?